Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell co-infusion to prevent graft rejection and graft-versus-host disease after nonmyeloablative allogeneic hematopoietic cell transplantation
2006-004101-26Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Sep 2006
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mesenchymal stem cells in graft-versus-host disease (GVHD) and graft rejection, sponsored by Centre Hospitalier Universitaire de Liège. Primary endpoints: Feasibility and safety and Hematopoietic engraftment and graft rejection. Started Sep 2006; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
graft-versus-host disease (GVHD)graft rejection
Beyond the preview
Go deeper on 2006-004101-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004101-26.